drugset / Trial / NCT05118919
A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC) patients as an oral administered local treatment in addition to Standard of Care (SoC) treatment.
Timeline
- Start
- 2022-02-09
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGP-014 | Unknown | — | Oral |